Adjuvant Chemotherapy Following Complete Resection of Soft Tissue
Sarcoma in Adults: A Clinical Practice Guideline by Figueredo, Alvaro et al.
Sarcoma (2002) 6, 5–18
Correspondence to: Dr. Alvaro Figueredo, Hamilton Regional Cancer Centre, 699 Concession Street, Hamilton, Ontario, Canada L8V
5C2. Fax: +1–905–575–6326; E-mail: alvaro.figueredo@hrcc.on.ca
1357–714X print/1369–1643 online/02/010005–14 © 2002 Taylor & Francis Ltd
DOI: 10.1080/13577140220127512
ORIGINAL ARTICLE
Adjuvant chemotherapy following complete resection of soft tissue 
sarcoma in adults: a clinical practice guideline
ALVARO FIGUEREDO1, VIVIEN H.C. BRAMWELL2, ROBERT BELL2, AILEEN M. DAVIS2, 
MANYA L. CHARETTE2, & THE MEMBERS OF THE CANCER CARE ONTARIO 
PRACTICE GUIDELINES INITIATIVE SARCOMA DISEASE SITE GROUP*
1Hamilton Regional Cancer Centre, Hamilton, Ontario, Canada, 2Cancer Care Ontario Program in Evidence-based Care, 
Hamilton, Ontario, Canada
Abstract
Purpose. To review the literature and make recommendations for the use of anthracycline-based adjuvant chemotherapy in
adult patients with soft tissue sarcoma (STS).
Patients. The recommendations apply to patients >15 years old with completely resected STS.
Methods. A systematic overview of the published literature was combined with a consensus process around the interpretation
of the evidence in the context of conventional practice to develop an evidence-based practice guideline.
Results. Four meta-analyses and 17 randomized clinical trials comparing anthracycline-based adjuvant chemotherapy versus
observation were reviewed. The Sarcoma Meta-Analysis Collaboration (SMAC) was the best analysis because it assessed
individual patient data and had the longest follow-up. The results of the SMAC meta-analysis together with data from more
recently published randomized trials, as well as our analysis of the toxicity and compliance data, are incorporated in this
systematic review.
Discussion. It is reasonable to consider anthracycline-based adjuvant chemotherapy in patients who have had removal of a
sarcoma with features predicting a high likelihood of relapse (deep location, size >5 cm, high histological grade). Although
the benefits  of adjuvant  chemotherapy  are most apparent  in  patients with extremity sarcomas,  patients with  high-risk
tumours at other sites should also be considered for such therapy.
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Introduction
Soft tissue sarcomas (STS) include a variety of malig-
nant tumours affecting mesenchymal tissues of the
extremities, trunk, head and neck and viscera. These
tumours  are  rare,  comprising  less  than  1%  of  all
malignancies.1  In  Canada,  the  actual  incidence in
1996 was 738 new cases.2 Regionalized multi-disci-
plinary units have been recommended to provide for
the best management of these patients. While wide
surgical resection of tumours remains the most effec-
tive  treatment,  30–50%  of  patients  develop  local
recurrences and/or distant metastases, many of which
eventually  lead  to  death.1,3,4  Predictors of  disease
relapse include high histological grade, size > 5 cm
and deep location. These factors indicate stage III in
the  International  Union  Against  Cancer  (UICC)
classification5  (please  see  Appendix  1  for  staging
information).  To  reduce  the  chances  of  disease
relapse  after  surgery,  adjuvant  radiotherapy  and
chemotherapy  have  been  advocated.  However,
results of individual trials have been inconclusive.1,3,4
Recently, several quantitative overviews of anthracy-
cline-based adjuvant chemotherapy trials have been
published.6–9  The  Sarcoma  Disease  Site  Group
(DSG) of the Cancer Care Ontario Practice Guide-
lines  Initiative  (CCOPGI)  deemed it  necessary to
investigate  whether  anthracycline-based  adjuvant
chemotherapy should be recommended as part of the
management  of  adult  patients  with  resected STS.
*Dale Anderson, Charles Catton, Jordi Cisa, Nigel ColterJohn, Jane Curry, C. Jay Engel, Victor Fornasier, Lorraine Hands,
Brian O’Sullivan, Maltibehn Patel, Shailendra Verma and Rebecca Wong also contributed to the development of this practice guide-
line. Please see the Cancer Care Ontario Practice Guidelines Initiative (CCOPGI) website (http:#dRwww.cancercare.on.ca/ccopgi/)
for a complete list of current Sarcoma Disease Site Group members.6 Figueredo et al.
This guideline did not consider non-anthracycline-
based chemotherapy regimens or neoadjuvant chem-
otherapy. The guideline was developed to specifically
answer the following questions:
1. What are the benefits of anthracycline-based adju-
vant  chemotherapy  in  adult  patients  with  com-
pletely resected soft tissue sarcomas, in terms of
local  disease  control,  systemic  recurrence  and
overall survival?
2. When these benefits are assessed in the context of
expected toxicities, in what circumstances should
adjuvant chemotherapy be recommended?
3. Are there  any  advantages  in using  combination
versus  single-agent  anthracycline-based  chemo-
therapy in the adjuvant setting?
Methods
Literature search strategy
The  databases  MEDLINE  (Ovid)  (1996–May
2001),  CANCERLIT  (Ovid)  (1996–March  2001)
and  the  Cochrane  Library  (Issue  2,  2001)  were
searched  for  trials  using  the  terms:  ‘sarcoma’
(Medical  Subject  Heading  [MeSH]),  ‘soft  tissue
sarcomas’ (text words), ‘postoperative’ (text word),
‘adjuvant therapy’ (text word) and ‘adjuvant chemo-
therapy’ (MeSH and text word). These terms were
then combined with the search terms for the follow-
ing  study  designs:  practice  guidelines,  systematic
reviews or meta-analyses, reviews, randomized con-
trolled trials and controlled clinical trials. In addition,
the Physician Data Query (PDQ) clinical trials data-
base  on  the  Internet  (http://cnetdb.nci.nih.gov/
trialsrch.shtml),  and  the  proceedings  of  the
1997–2001 annual meetings of the American Society
of  Clinical  Oncology  (ASCO)  were  searched  for
reports of new or on-going trials. Relevant articles
and  abstracts  were  selected  and  reviewed  by  one
member of the Sarcoma DSG and methodologists,
and  the  reference  lists  from  these  sources  were
searched for additional trials.
Study selection
Articles were selected for inclusion in this systematic
review of the evidence if they met the following criteria:
1. RCTs or overviews of RCTs comparing anthracy-
cline-based adjuvant chemotherapy to observation
in patients with completely resected STS.
2. Patients were at least 15 years of age.
3. Data provided on outcomes of overall and disease-
free survival.
4. Abstracts of trials were considered.
Synthesizing the evidence
The  intent  was  to  perform a  meta-analysis  of  the
major outcomes, disease relapse  and survival. If  a
previous meta-analysis had good methodology, those
published results were used as evidence. To investi-
gate outcome results not reported by previous meta-
analyses (i.e., single-agent doxorubicin versus combi-
nation chemotherapy, toxicity, compliance), the data
of previous meta-analyses or of individual RCTs were
reanalyzed by the Sarcoma DSG using the software
package  Metaanalyst0.098  (provided  by  J.  Lau,
Boston, MA, USA). To estimate overall effects, and
to  maintain uniformity with previous analyses, the
odds ratio (OR) (95% confidence intervals [CI]) is
reported  according  to  the  fixed  effects  model  of
Mantel-Haenzel and Peto.  Estimates for OR > 1.0
favour  the  control  group  (observation),  whereas
OR < 1.0  favour  the  treatment  group  (adjuvant
chemotherapy).
Guideline development process
This  guideline  was  developed  by  the  CCOPGI
Sarcoma  DSG,  using  the  methodology  of  the
Practice Guidelines Development Cycle.10 Evidence
was  selected and  reviewed by  one member of  the
Sarcoma DSG and methodologists. The guideline is
a convenient and up-to-date source of the best avail-
able evidence on adjuvant chemotherapy following
complete  resection  of  STS  in  adults,  developed
through systematic reviews, evidence synthesis and
input from practitioners in Ontario. It is intended to
enable evidence-based practice. The Practice Guide-
lines Initiative is editorially independent of Cancer
Care Ontario and the Ontario Ministry of Health and
Long-Term Care.
Practitioner  feedback  was  obtained  through  a
mailed survey consisting of items asking for ratings on
the  quality  of  the  draft  practice  guideline,  and
whether the draft recommendations should serve as a
practice  guideline.  Final  approval  of  the  original
guideline report was obtained from the PGCC. The
CCOPGI  has  a  formal  standardized  process  to
ensure the currency of each guideline report. This
consists of periodic review and evaluation of the sci-
entific literature, and where appropriate, integration
of this literature with the original guideline informa-
tion.
Results
Literature search results
Four meta-analyses6–9  and 17  RCTs11–31  met the
inclusion criteria and were reviewed. Fourteen of the
RCTs were included in the overview by the Sarcoma
Meta-Analysis  Collaboration  (SMAC)11–28  which
also included updated individual patient data. Three
RCTs29–31 were published after the  SMAC meta-
analysis  and  are  discussed  in  this  overview.  The
chemotherapy  regimens  used  in  the  RCTs  are
described in Appendix 2.Adjuvant chemotherapy for resected soft tissue sarcoma 7
Meta-analyses
The first quantitative overview by Jones et al.6 was
literature-based and reported in abstract form only.
It  included  13  published  trials  of  doxorubicin-
containing adjuvant chemotherapy in resected STS
at  any  location.  Eligible  trials  compared  adjuvant
chemotherapy  to  observation.  Statistically  signifi-
cant benefits favouring adjuvant chemotherapy were
observed for overall survival (9% absolute benefit;
p = 0.016),  time  to  local  recurrence  (p = 0.0003)
and metastases (p = 0.0016). There was also a sug-
gestion of increased survival benefit for combination
chemotherapy  versus  doxorubicin  alone,  and  of
decreased local recurrence when chemotherapy was
combined with radiation therapy (RT). The authors
found that reporting of outcomes was variable and
suggested  a  centralized  registry  with  standardized
reporting  of  results  for  individual  patient  data
assessment.
The  second  literature-based  meta-analysis  by
Zalupski et al.7 was limited to nine published trials of
adjuvant chemotherapy in patients with STS of the
extremities.  Adjuvant  chemotherapy  significantly
improved  both  overall  survival  and  disease-free
survival rates by 10 and 15%, respectively, compared
to observation.
Finally, the third literature-based meta-analysis by
Tierney et al.8 included 15 published trials compar-
ing adjuvant chemotherapy to no chemotherapy in
resected  STS  of  any  location.11,14,16,18,20–28  A
significant improvement in overall survival (12% at
5 years;  p = 0.0002)  was  noted  for  the  treated
patients. Because of concerns with potential biases in
published data and the inability to investigate patient
subgroups, a meta-analysis using individual patient
data was proposed.
This task was undertaken by the Sarcoma Meta-
analysis Collaboration9 consisting of European and
North  American investigators. Although the above
three previous literature-based meta-analyses6–8 had
suggested  significant  improvements in  overall  sur-
vival, disease-free survival and local recurrence with
the use of adjuvant chemotherapy, the conclusions of
these analyses were weakened by the possibility of
publication  biases  and  relatively  short  follow-up
times in the published results. Therefore, the collab-
orative  effort  was  to  include  both  published  and
unpublished  results  as  well  as  updated  individual
patient data, in order to obtain more reliable results
and to enable subgroup analyses.
The  search  for  data  was  broad;  it  included the
MEDLINE, CANCERLIT and EMBASE databases
for  published  material,  the  UK  Committee  on
Cancer Research of Clinical Trials and the US PDQ
of  Clinical  Protocols  for  unpublished  trials.  The
search extended from 1966 to 1996. The terms used
in the search were not described. Reference lists of
publications were also examined. Eligible studies ran-
domly  assigned  patients  with  localized  resectable
STS to receive adjuvant chemotherapy or no chemo-
therapy. Potential biases were avoided by including
published and unpublished results and by updating
individual patient data through the original investiga-
tors. The methods for combining data were clearly
reported and appeared appropriate. Heterogeneity of
results  was  investigated.  The  conclusions  were
supported by the data analysis, including clinically
relevant subgroup analyses.
The overall sample included 1568 patients in 14
RCTs  of  doxorubicin-based  adjuvant  chemother-
apy.11–28  The  published  studies  are  described  in
Table 1. One unpublished trial by the Swiss Group
for  Clinical  Cancer  Research  (SAKK)  was  also
included in the SMAC meta-analysis. The chemo-
therapy  regimens have  been described in detail in
Appendix 2.  The majority  of  patients  (74%)  were
15–60 years of age, and 54% were female. Seventy-
four percent of patients had primary tumours, and
11%  had  resected recurrent tumours. The  disease
affected the extremities in 58% of patients, the trunk
in 12%, the uterus in 17% and other sites in 10%.
The  most  common  histological  types  of  tumours
were malignant fibrous histiocytoma (20%), leiomy-
osarcoma (12%), synovial sarcoma (10%) and liposa-
rcoma (9%). The histological type was not available
in 18% of cases. Most tumours (67%) were of high-
grade malignancy, but in 28% of cases grade was not
available. Complete tumour resections were done in
76% of patients, marginal resections were performed
in 15% of the cases and assessment was not available
in 9% of cases. Radiotherapy was used in 47% of
cases.
The adjuvant chemotherapy consisted of doxoru-
bicin alone in six RCTs comprising 727 patients, and
of doxorubicin combined with other drugs in eight
RCTs comprising 844 patients. The drugs added to
doxorubicin were cyclophosphamide in seven trials,
vincristine in four trials, dacarbazine in three trials,
methotrexate in three trials, actinomycin D in two
trials and ifosfamide in a single small unpublished
trial (SAKK) (Table 1).
All  reported  results  were  given  as  OR,  hazard
ratios, or as risk differences (RD) with 95% CI using
the fixed effects model of Peto. Potential heterogene-
ity  of  results  was  explored  and  no  significant
(p < 0.10)  values  were  observed.  One  study13
recorded recurrence, but did not distinguish between
local and distant recurrence and, therefore, was not
included in the analyses of these outcome measures9.
In patients receiving adjuvant chemotherapy, there
was  a  non-significant  trend  for  increased  overall
survival (Fig. 1 and Table 2) with a RD of 4% (95%
CI, -1  to  9%)  when  compared with  patients  who
received  no  adjuvant  chemotherapy.  Disease-free
survival was significantly increased in treated patients
with  an  absolute  RD  of  10%  (95%  CI,  5–15%;
p = 0.0001) at 10 years. This difference was mostly
due to patients who were free of metastases, in whom8 Figueredo et al.
there  was  a  10%  difference  (95%  CI,  5–15%;
p = 0.0003) (Table 2). The difference for local recur-
rence  was  smaller,  but  still  statistically  significant
(RD, 6%; 95% CI, 1–10%; p = 0.016). These pooled
results  were  not  changed  by  excluding  patients
younger than 15 years of age, the presence of local
recurrence  or  metastases,  nor  whether  patients
received induction chemotherapy.
Although tests  of  the  overall data  did not show
significant statistical heterogeneity (p < 0.10), there
was evidence of clinical heterogeneity, indicated by
the  wide  range  of  age  groups,  tumour  locations,
tumour sizes, types and grades of malignancy, surgi-
cal treatments, use of adjuvant RT and regimens of
chemotherapy. The results of these subgroup analy-
ses were difficult to interpret. The SMAC authors
stated  ‘For  overall  survival,  there  was  no  clear
evidence to suggest that any subgroup benefited more
or less from adjuvant chemotherapy … There was
some  suggestion  that  men  benefited  more  than
women from  chemotherapy  [but  this  was  felt  to  be
biologically implausible]. Among patients with lesions
of  the  extremities  (376  deaths,  886  patients),  the
hazard ratio was 0.80 (p = 0.029), equivalent to a 7%
absolute benefit at 10 years. This group had the clear-
est evidence of a treatment effect on survival. The
wide confidence intervals for the other sites reflect the
small numbers, and there was no clear evidence that
the results differed from those for extremity sarcomas
(p = 0.58).’ There was no evidence of a differential
effect  of  chemotherapy  for  any  of  the  subgroups
considered for relapse-free survival.
The conclusion of the SMAC project was that dox-
orubicin-based  adjuvant  chemotherapy,  following
resection of STS, is associated with a significant pro-
longation of the disease-free interval (mostly due to
delay  in  metastases)  and  a  trend  for  increased
survival. The largest benefit in survival was  in the
subgroup of patients with extremity sarcomas, with
an absolute 7% benefit at 10 years. Converting the
RD to the number needed to treat (NNT) resulted in
a  value  of  14  patients  requiring  treatment  with
adjuvant chemotherapy to delay one death.
Treatment effects according to chemotherapy used
All of the adjuvant chemotherapy regimens investi-
gated  by  the  SMAC  contained  doxorubicin,  but
seven of them also included other drugs (Table 1).
The dose of doxorubicin ranged from 50 to 90 mg/m2
per course, with total cumulative doses between 400
and 550 mg/m2. A dose–response relationship was
investigated but not detected in any of the meta-anal-
yses.6–9 Using data from the SMAC paper,9 a new
analysis was performed evaluating the effect of treat-
ment  with  doxorubicin  alone  versus  doxorubicin
combined with other drugs. For patients treated with
single-agent  doxorubicin  versus  patients  who
received  no  adjuvant  chemotherapy,  the  mortality
OR was 0.80 (95% CI, 0.60–1.07), compared with
0.89 (95% CI, 0.67–1.18) for patients on combined
chemotherapy versus those randomized to observa-
tion. The OR for recurrence for patients treated with
single-agent doxorubicin versus those who received
Table 1. Randomized trials of doxorubicin-based adjuvant chemotherapy in resected soft tissue sarcomas in adults (data from 13 
published studies included in SMAC meta-analysis)
Chemotherapy No. of patients assigned to 
each group (entered/
evaluable)
Trial (Ref.) Disease sites Chemo.
Dose per 
course*
Dose 
intensity†
Total 
dose‡ RT Control Dox.
GOG(11) Ut Dox 60 20 480 No 112/81 113/75
DFCI(12) Ex,RP,HN,Tr Dox 90 30 450 Yes 22/22 20/20
ECOG(13) Ex,RP,HN,Tr Dox 70 23.3 490 No NA/13 NA/17
SSG(14) Ex,HN,Br,Tr,Abd Dox 60 15 540 Some 119/88 121/93 
Rizzoli(15,16) Ex Dox 75 25 450 Some 35/35 24/24 
IGSG(18,19) EX,RP,HN,Tr Dox 70–90 23.3–26.7 450 Some NA/43 NA/39 
MDAH(20) Ex VACAR 60 15 420 Yes 24/23 22/20 
Mayo(21,22) Ex,Tr VAC/VAD 50 8.3 200 No NA/31 NA/30
NCI(23,24) Ex AC/MTX 50–70 12.5–15.6 550 Yes 28/28 39/37
NCI(25,26) HN,Tr,Br AC/MTX 50–70 12.5–15.6 550 Yes 14/27 17/30
NCI(25,26) RP AC/MTX 50–70 12.5–15.6 550 Yes 7/16 8/21 
EORTC(27) Ex,RP,Tr,HN,Ut CYVADIC 50 12.5 400 Yes 234/172 234/145 
Bergonié(28) Ex,RP,HN,Tr CYVADIC 50 8.33 500 Yes NA/28 NA/31
Note: Abd, abdominal; AC, doxorubicin+cyclophosphamide; Br, breast; Chemo., chemotherapy; CYVADIC, cyclophos-
phamide+vincristine+doxorubicin+dacarbazine;  Dox,  doxorubicin;  Ex,  extremities;  HN,  head  and  neck;  MTX,  meth-
otrexate+leucovorin; NA, data  not available;  RP, retroperitoneal; RT, radiation therapy; Tr, trunk; Ut, uterine; VAC,
vincristine+cyclophosphamide+actinomycin  D;  VACAR,  vincristine+doxorubicin+cyclophosphamide+actinomycin  D;
VAD, ncristine+doxorubicin+dacarbazine.
* Dose per course in mg/m2.
† Dose intensity in mg/m2 per week considering only the first four courses of chemotherapy.
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no  adjuvant  chemotherapy  was  0.71  (95%  CI,
0.53–0.96), similar to the OR for patients receiving
doxorubicin-containing combination adjuvant ther-
apy  versus  patients  randomized  to  no  adjuvant
chemotherapy (OR, 0.69; 95% CI, 0.51–0.94).
Adverse effects
Among the 14 trials included in the SMAC, toxicity
data were not available  for one unpublished study
(SAKK) and for one published trial.20 Reporting of
Fig. 1. Meta-analysis of the effects of adjuvant chemotherapy versus observation. Squares represent hazard ratios; area is proportional
to amount of information available in trial; bars represent 95% confidence interval (CI) (inner limit) and 99% CI (outer limit).
Diamonds  represent  overall  hazard  ratios  for  results  of  all  trials  combined  —  extremes  of  diamond  give  95%  CI;  O–E,
observed–expected; RFI, recurrence-free interval; RFS, recurrence-free survival. Note: statistical heterogeneity was p>0.10 in all four
analyses: local recurrence-free interval, p=0.17; distant recurrence-free interval, p=0.86; overall recurrence-free survival, p=0.75;
overall  survival,  p=0.54.  (Used  with  permission:  Sarcoma  Meta-analysis  Collaboration.  Adjuvant  chemotherapy  for  localized
resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Lancet 1997; 350: 1647–54.)10 Figueredo et al.
adverse effects in the other trials was not standard-
ized. Some trials reported mostly qualitative assess-
ments of toxicity,11–13,15,21,28 while others reported
quantitative data according to standard toxicity grad-
ing scales.14,17,23–27 Adverse effects frequently con-
sisted  of  alopecia,  fatigue,  anorexia,  nausea  and
vomiting, leucopenia or neutropenia, thrombocyto-
penia,  infections,  mucositis  and  cardiotoxicity.
Alopecia  was  considered  significant  in  50%27  to
90%13,21,25  of  patients.  Nausea  and vomiting was
mild to moderate in some trials; it was considered
severe in 22–50% of patients in other trials.13,14,17,19
Various degrees of nadir or treatment day leucopenia
or neutropenia were described in all trials, but neu-
tropenic  sepsis  was  uncommon and  only  a  single
patient  was  reported  as  dying  due  to  infection.27
Severe thrombocytopenia was rare but it contributed
to death in one patient with concurrent neutropenic
sepsis  and  multiple organ  failure.27  Cardiotoxicity
was generally reported and consisted of arrhythmias
and  congestive  heart  failure,  the  latter  leading  to
death in six patients.14,19,21,25,26  While the reported
adverse effects could be attributed to doxorubicin,
there were other  side-effects associated with  other
drugs.  Severe  peripheral  neuropathy  induced  by
vincristine  was  reported  in  four  (3.2%)  of  126
patients treated with cyclophosphamide, vincristine,
doxorubicin and dacarbazine.27 Cystitis was noted in
four (7.8%) patients treated with doxorubicin, cyclo-
phosphamide, methotrexate and leucovorin and con-
current  RT;25,26  another  patient  had  reduced
creatinine  clearance  on  high-dose  methotrexate.26
Diarrhea occurred in two (8%) of 30 patients receiv-
ing vincristine, doxorubicin, cyclophosphamide and
actinomycin D.21
The available quantitative toxicity data has been
tabulated for toxic deaths and major toxic events such
as severe infections and cardiotoxicity (Table 3). The
overall rate of toxic deaths was nine in 523 patients
(1.7%), and was the same for patients treated with
doxorubicin alone  or  combined with  other  drugs.
The overall rate of cardiotoxicity was 25 cases among
494  patients  (5.1%).  Those  receiving  doxorubicin
alone  had  a  5.6%  cardiotoxicity  rate,  while  the
cardiotoxicity  rate  for  doxorubicin combined with
other  drugs  was  4.4%.  Severe  infections occurred
more commonly in patients receiving multiple drug
chemotherapy  with  a  rate  of  3.1%  (seven  of  226
Table 2. Pooled results of adjuvant chemotherapy in adult patients with resected soft tissue sarcomas (data from the Sarcoma Meta-
analysis Collaboration)
Survival rate No. of trials No. of pts. Odds ratio (95% CI) P value Risk difference (95% CI)†
Overall 14 1544 0.89 (0.76–1.03) 0.12 -0.04 (-0.09 to -0.01)
Overall‡ 12 886 0.80 (NA) 0.029 -0.07 (NA)
Disease-free 14 1366 0.75 (0.64–0.87) 0.0001 -0.10 (-0.15 to -0.05)
Without local recurrence 13* 1315 0.73 (0.56–0.94) 0.016 -0.06 (-0.10 to 0.01)
Without metastases 13* 1315 0.70 (0.57–0.85) 0.0003 -0.10 (-0.15 to -0.05)
Note: CI, confidence interval; NA, data not available; pts, patients.
* ECOG trial (13) not included; data not available. 
† A minus (-) sign in front of the risk difference indicates a decrease in risk for treated patients versus controls.
‡ Only patients with extremity sarcomas.
Table 3. Severe toxicity of adjuvant chemotherapy in adult patients with resected soft tissue sarcomas (data from published papers)
Trial (Ref.) Chemotherapy*
No. of evaluable 
patients
No. of toxic
deaths (%)
No. of pts
infected (%)
No. of pts with 
cardiotoxicity (%)
GOG(11) Dox 75 0 0 6 (8.0)
DFCI(12) Dox 20 1 (5.0) 1(5.0) 2 (10.0)
ECOG(13) Dox 17 0 NA 0
SSG(14) Dox 93 3 (3.2) 0 4 (4.3)
Rizzoli(15,16) Dox 24 0 0 1 (4.2)
ISG(18,19) Dox 39 NA 0 2 (5.1%)
All Dox alone Dox 268 4/229 (1.7) 1/251 (0.4) 15/268 (5.6)
MDAH(20) VACAR 20 NA NA NA
Mayo(21,22) VAC/VAD 30 1(3.3) 1 (3.3) 0
NCI(23,24) AC/MTX 37 0 NA NA
NCI(25,26) AC/MTX 30† 1(3.3) 2 (6.7) 5 (16.7)
NCI(25,26) AC/MTX 21‡ 2 (9.5) 3 (14.3) 3 (14.3)
EORTC(27) CYVADIC 145 1 (0.7) 1 (0.7) 2 (1.4)
Bergonié(28) CYVADIC 31 0 NA NA
All Dox + other Dox + other 314 5/294 (1.7) 7/226 (3.1) 10/226 (4.4)
All Dox +/- other 582 9/523 (1.7) 8/477 (1.7) 25/494 (5.1)
Note: Infected, severe infections; NA, data not available.
* Chemotherapy: Please see footnote of Table 1.
† Includes 13 patients treated outside the randomized trial.
‡ Includes 13 patients treated outside the randomized trial.Adjuvant chemotherapy for resected soft tissue sarcoma 11
patients) versus 0.4% (one of 251 patients) in those
receiving only doxorubicin (Table 3).
Overall, no correlation was found between chemo-
therapy toxicity and the use of RT (data not shown).
Only three trials did not use RT11,13,21 and another
omitted the use of doxorubicin during RT.28 Of note,
however, is that one trial of combined RT and che-
motherapy versus RT alone in patients with retro-
peritoneal sarcomas was terminated because of poor
results  and  toxicity  in  the  combined  treatment
group.25
Compliance with chemotherapy
Compliance  data  were  not  reported  in  six
trials,12,13,17,20,25,26  reported in a limited manner in
three trials,15,21,28 and investigated in more detail and
correlated  with  major  outcomes  in  four  other
trials.11,14,24,27 Compliance data were not available
for  the  unpublished trial  (SAKK)  included in  the
SMAC meta-analysis. In Table 4, we have tabulated
compliance with chemotherapy according to whether
patients received any treatment, or had minor or major
reductions of chemotherapy. We considered patients
receiving at  least four courses of  chemotherapy as
having a minor reduction of treatment.
Overall compliance with treatment was similar for
both single-agent doxorubicin and doxorubicin com-
bined with other drugs. Of 276 patients randomized
to receive doxorubicin alone, data were not available
for 76 patients. Of the data available for 200 patients,
107 (53.5%) received full dose treatment and 177
(88.5%) received at least four courses of treatment.
Among 314 patients randomized to receive doxorubi-
cin combined with other drugs, data were only avail-
able  for  243  patients.  Of  these  243  patients,  143
(58.8%)  received  full  treatment  and  184  (75.7%)
received  at  least  four  courses  of  chemotherapy
(Table 4).
Recent randomized clinical trials
A search for trials published after the SMAC over-
view uncovered three RCTs.29–31 Investigators at the
University  Hospital  in  Vienna  reported  on  59
patients recruited into an RCT between 1992  and
1999, which was stopped because of poor accrual.29
These patients had mostly STS of the extremities,
grade II or III, and had wide or marginal resection.
Post-operatively, the patients were randomized to RT
alone (51 Gy hyperfractionated), or to the same RT
plus  dose-intensive chemotherapy  with  ifosfamide,
dacarbazine  and  doxorubicin, with  the  support  of
granulocyte-colony stimulating factor (G-CSF) after
wide or marginal resection.29 After a mean observa-
tion period of 41±19.7 months, there was a non-sig-
nificant decrease in local relapses, all relapses and
death  for the  group of  patients  receiving adjuvant
chemotherapy. In the subgroup of patients with grade
III tumours, disease-free survival (but not overall sur-
vival)  was  significantly  improved by  chemotherapy
(p = 0.03). Toxicity was moderate with no fatalities
and no episodes of neutropenic sepsis or cardiomyop-
athy. One patient in the RT group and three patients
in  the  RT  plus  chemotherapy  group  had  local
complications related to the underlying bone.
Another trial was reported by a group of Italian
investigators.30 The trial is reported for 104 patients
with resected, high-grade, primary or recurrent STS
of the extremities and girdles randomized to either
observation or five courses of intensive adjuvant che-
motherapy with epirubicin and ifosfamide supported
Table 4. Compliance with adjuvant chemotherapy (data from published papers)
Trial (Ref.) Chemotherapy*
Total no.
of pts
No. of no 
treatment (%)
No. of major 
treatment reduction 
(%)
No. of minor 
treatment reduction 
(%)
No. of
full treatment 
(%)
GOG(11) Dox 83 8 (9.6) 6 (7.2) 14 (16.9) 55 (66.3)
DFCI(12) Dox 20 NA NA NA NA
ECOG(13) Dox 17 NA NA NA NA
SSG(14) Dox 93 NA 10 (10.8) 54 (58.1) 29 (31.2)
Rizzoli(15,16) Dox 24 0 0 2 (8.3) 23 (95.8)
ISG(18,19) Dox 39 NA NA NA NA
All Dox-alone Dox 276 8/107 (7.5) 16/200 (8.0) 70/200 (35.0) 107/200 (53.5)
MDAH(20) VACAR 20 NA NA NA NA
Mayo(21,22) VAC/VAD 30 0 5 (16.7) 2 (6.7) 23 (76.7)
NCI(23,24) AC/MTX 37 0 0 3 (8.1) 34 (91.9)
NCI(25,26) AC/MTX 30† NA NA NA NA
NCI(25,26) AC/MTX 21‡ NA NA NA NA
EORTC(27) CYVADIC 145 19 (13.1) 34 (23.5) 16 (11.0) 76 (52.4)
Bergonié(28) CYVADIC 31 0 1 (3.2) 20 (64.5) 10 (32.3)
All Dox + other Dox + other 314 19/243 (7.8) 40/243 (16.5) 41/243 (16.9) 143/243 (58.8)
Note: NA, data not available.
* Chemotherapy: please see footnote in Table 1.
† Includes 13 patients treated outside the randomized trial.
‡ Includes 13 patients treated outside the randomized trial.12 Figueredo et al.
by G-CSF. After a median follow-up of 59 months,
an intention to treat analysis showed median disease-
free survival times of 48 versus 16 months (P=0.04)
and median overall survival times of 75  versus 46
months  (p = 0.03)  for  chemotherapy  and  control
groups, respectively. It should be noted that although
there is a delay in distant relapse in the chemotherapy
arm, at 4 years the distant relapse rates are the same
between the arms (44 and 45%). There remains a sig-
nificant difference in 4-year overall survival with an
absolute number of seven fewer deaths due to tumour
in the chemotherapy arm. However, although 5-year
median follow-up may be sufficient to observe the
majority  of  distant  relapses  in  high  grade  STS,
improved treatments in supportive care may extend
survival for patients with metastases, and it is possible
they may die at different rates in the two arms; only
longer follow-up will clarify this point. The toxicity
was mainly hematological: 35% of patients had grade
4  leukopenia,  33%  developed  neutropenic  sepsis,
24% required packed red blood cell transfusions and
4% had grade 4 thrombocytopenia. No cardiotoxicity
was  observed  using  ventricular  ejection  fraction
measurements. Seven  patients  did  not  receive the
prescribed chemotherapy and four patients did not
complete treatment due to toxicity after two, three,
four and five courses of treatment.
Another Italian  group from Siena performed an
adjuvant chemotherapy trial on 88 patients random-
ized after surgery to observation or chemotherapy.31
The chemotherapy consisted of epirubicin during the
first half of the study, and epirubicin combined with
ifosfamide for the rest of the study. Overall, among
the 81 evaluable patients, patients on adjuvant che-
motherapy had improved 5-year disease-free survival
(65 vs. 41%; p = 0.01) and a trend for overall survival
(72  vs.  47%;  p = 0.06)  compared  to  patients  not
receiving chemotherapy. It should be noted that only
19  patients  received an  intensive epirubicin/ifosfa-
mide combination; the remainder in the chemother-
apy arm received single agent epirubicin. Given that
this small study is reported only in abstract form, it
should be interpreted with caution.
Practitioner feedback
The draft recommendations were sent to 78 practi-
tioners in Ontario. The sample consisted of 26 med-
ical  oncologists,  14  radiation  oncologists,  32
surgeons, four gynecologists and two pathologists. Of
the 46 (61%) surveys returned, 88% agreed with the
recommendations and 70% approved the recommen-
dations as a practice guideline. Six (18%) respond-
ents provided written comments. These comments
were reviewed by the members of the Sarcoma DSG,
and modifications were made  to  the  document to
address these comments.
One practitioner commented that uterine sarcomas
have traditionally been treated somewhat differently
than other STS, rightly or wrongly. This practitioner
felt that the effectiveness of the guideline could be
improved by: (1) providing a rationale for including
uterine STS in the current analysis and draft recom-
mendations, or (2) excluding uterine sarcomas from
the analysis, or (3) making specific comments in the
document about these tumours. As a result of this
comment, a statement that no specific recommenda-
tion can be made about uterine sarcomas was added
to the Practice Guideline.
Another  practitioner  commented  that  assessing
tumour grade and its role in tumour responsiveness
should be considered. The Sarcoma DSG considered
that the guideline document already addressed this
issue.
Discussion
The  benefits  in  preventing  disease  relapse  and
improving patient survival, especially in patients with
resected STS of the  extremities, although modest,
compare favourably with results for adjuvant chemo-
therapy in early breast cancer32,33 and stage III colon
cancer,34  where  adjuvant  chemotherapy  is consid-
ered  standard  care.  The  SMAC database  used  to
draw  these  conclusions is,  however, much smaller
than  similar  databases  for  the  other  common
tumours.  With  this  limitation,  doxorubicin-based
adjuvant chemotherapy can be reasonably considered
for  adult  patients  with  resected  STS  of  the
extremities  at  high  risk  for  recurrence (deep  high
grade tumours > 5 cm in size)1,5 and at low risk of
adverse effects (no underlying diseases, particularly
cardiovascular).
Despite some variation in the results of individual
trials, all meta-analyses have shown that in patients
with  resected STS of  any  type,  doxorubicin-based
adjuvant  chemotherapy  significantly  prolongs
disease-free survival. The 10% absolute increase in
disease-free survival at 10 years shown in the SMAC
individual  patient  data  overview  is  due  both  to
reduced distant metastases and local recurrences. In
spite of this reduction of relapses, there is only a trend
for increased survival for the entire group of sarcoma
patients (Table 2).
Although  the  data  are  consistent  with  modest
survival  benefits  across  all  sarcomas  examined,
there  are clues as  to  potential  patient subgroups
which  are  more  likely  to  benefit.  In  the  SMAC
meta-analysis,  a  statistically  significant  survival
benefit associated with doxorubicin-based chemo-
therapy  (7%  absolute  increase  in  survival  at  10
years) was found in 886 patients with extremity sar-
comas. The next two  largest groups are those of
uterine  and  trunk  sarcomas  with  263  and  182
patients,  respectively.  Few  retroperitoneal  sarco-
mas  are  included,  and  the  main  contributing
study26 was terminated early because of an adverse
effect  of  chemotherapy  and  substantial  toxicity.Adjuvant chemotherapy for resected soft tissue sarcoma 13
Only 30 patients in the SMAC meta-analysis had
abdominal sarcomas.14 Furthermore, only 24% of
patients in the database were above age 60. Many
of the trials excluded patients above age 65, or in
some cases 70. Thus, it is difficult to generalize the
beneficial results detected in the SMAC overview
to patients with retroperitoneal tumours, or those
above the age of 70 years. Finally, there was no dif-
ference  in  the  reduction  of  mortality  or  disease
recurrence  between  single-agent  or  combination
adjuvant therapy with doxorubicin.
The information related to the effect of chemother-
apy  on  local  control  should  be  interpreted  with
caution. In the SMAC meta-analysis, 15% of patients
treated with chemotherapy experienced local recur-
rence (101 of 659 cases) compared with 19% (126 of
656 cases) in the control group. These relatively high
rates of local recurrence are of concern. Local treat-
ment is most important in the initial management of
sarcomas.  In  extremity  sarcomas,  wide  surgical
excision, supplemented by radiation in cases where
tumour  size  or  location  limits  the  procedure, can
achieve local control in over 90% of cases.35–38 How-
ever, the meta-analysis did not separately assess the
local  recurrence rate  for  extremity  sarcomas.  The
higher  rate  of  local  recurrence  reported  may  be
explained  by  the  inclusion  of  non-extremity
sarcomas, which are known to have a higher rate of
local failure.35
The consideration of doxorubicin-based adjuvant
chemotherapy for patients with STS at non-extremity
locations is more problematic. There are limited data
about  these  tumours,  and  the  available  trials  are
inconclusive as  to  benefits  with  respect  to  disease
relapse  or  survival.  The data  on  uterine sarcomas
consist mostly of patients investigated in a single trial
with negative results; therefore, no specific recom-
mendations can be made about these tumours. Few
trials  investigated  patients  with  retroperitoneal
sarcomas, and the observed adverse effect of chemo-
therapy when combined with radiation, would sug-
gest that doxorubicin-based adjuvant chemotherapy
should  not  be  recommended  for  retroperitoneal
sarcomas. There are insufficient data on patients with
gastrointestinal stromal tumours (GIST) to recom-
mend  doxorubicin-based  adjuvant  chemotherapy.
GIST represent a discrete group of tumours with a
mutation of the proto-oncogene c-kit and overexpres-
sion of the associated tyrosine kinase. Although these
tumours are generally resistant to chemotherapy, a
specific inhibitor STI 571 or imatinib, induces remis-
sion in approximately half the cases with advanced
disease.39 The role of this drug as an adjuvant has not
yet been investigated.
Benefits in preventing disease relapse and improv-
ing survival are achieved at the cost of a significant
degree  of  toxicity,  including  a  5%  rate  of  life-
threatening  drug-induced events  and  a  2%  toxic
fatality  rate.  Although  most  toxicity  is  acute  (for
example, nausea and vomiting, infections, cardiac
arrhythmias), other events, such as cardiomyopathy,
have  long-term consequences. All these untoward
effects have a major impact on treatment compli-
ance (Table 4) and will affect patient quality of life,
which unfortunately has not been specifically mea-
sured.
Strategies for reducing anthracycline-induced car-
diotoxicity should be investigated.40 This approach
may have limitations, as the use of doxorubicin by
infusion  compared  with  the  drug  given  by  bolus
reduced not only cardiotoxicity but also disease-free
and overall survival.41 Because of problems with tox-
icity  and  drug  compliance,  patient  quality  of  life
should be investigated and reported. As the meta-
analyses have shown, a large number of patients will
be required to demonstrate significant differences in
outcomes, and these trials will require international
cooperation.
In a meta-analysis of the 14 trials included in the
SMAC  report,  the  benefit  for  doxorubicin-based
combination chemotherapy versus observation was
similar  to  the  benefit  of  single-agent  doxorubicin
versus observation. The combination regimens used
in these trials are rarely used today. On the other
hand, combination of  doxorubicin with  ifosfamide
(the second most active drug in advanced STS) is
only represented by a small study of 31  patients.9
Three recently reported trials,29–31 using dose-inten-
sive ifosfamide with doxorubicin and dacarbazine29
or epirubicin30,31 under cover of G-CSF, have dem-
onstrated  either  a  trend29,31  or  a  significant
improvement30 of disease-free and overall survival.
This approach is also being investigated in a large
EORTC-sponsored  RCT,  and  it  should  be  sup-
ported to determine precisely the potential advantage
of combination chemotherapy.
Practice guideline
Target population
These recommendations apply to adult patients with
completely resected soft tissue sarcoma.
Recommendations
￿ It  is  reasonable to  consider anthracycline-based
adjuvant chemotherapy in patients who have had
removal of a sarcoma with features predicting a
high likelihood of relapse (deep location, size > 5
cm, high histological grade). These features corre-
spond  to  International  Union  Against  Cancer
(UICC) stage III.
￿ Although the benefits of adjuvant chemotherapy
are most apparent in patients with extremity sarco-
mas  (7%  RD  for  overall  survival  at  10 years),
patients  with  high-risk  tumours  at  other  sites
should also be considered for such therapy.14 Figueredo et al.
Qualifying statements
￿ There is  insufficient evidence on  patients  with
retroperitoneal  sarcomas  and  stromal  cell
tumours of the gastrointestinal tract to make rec-
ommendations for adjuvant chemotherapy. The
risk  of  serious  toxicity  when  chemotherapy  is
combined with radiation therapy is of major con-
cern.  Data  on  uterine  sarcomas  derive  mostly
from a single trial with negative results; therefore,
no specific recommendations can be made about
these tumours.
￿ Risks of severe persistent adverse effects of adju-
vant  chemotherapy,  such  as  cardiomyopathy,
should be carefully evaluated and balanced against
the expected benefit, particularly in patients aged
70 years or older and those with significant co-
morbidity.
￿ There are insufficient data to determine whether
single-agent or combination doxorubicin chemo-
therapy  should be  recommended. This decision
should take  into account  issues such as  patient
preference/convenience,  likely  adverse  effects,
costs and available resources.
Key evidence
￿ Considering all  resected  STS  patients,  doxoru-
bicin-based  adjuvant  chemotherapy  significantly
reduces all recurrences, with an absolute benefit of
10% (95% CI, 5–15%; p = 0.0001) at 10 years.
There is only a non-significant effect for survival,
with an absolute benefit of 4% at 10 years (95%
CI, -1 to 9%). Considering only patients with STS
of the extremities, the benefit of adjuvant chemo-
therapy is 7% at 10 years (p = 0.001). A recently
reported small randomized study using high-dose
epirubicin  and  ifosfamide  in  large  high-grade
extremity sarcomas showed improved disease free
(p = 0.04)  and overall survival (p = 0.03).  Most
chemotherapy regimens produce significant toxic-
ity.
Future research
￿ Patients should be encouraged to participate in
clinical trials comparing adjuvant chemotherapy
versus observation to further characterize bene-
fits.
Practice guideline date
Completed 10  November  2000.  Updated 13  June
2001.
Cancer Care Ontario Practice Guidelines Initiative
(CCOPGI)  practice  guidelines  are  reviewed  and
updated  regularly.  Please  visit  the  CCOPGI
website at http://www.cancercare.on.ca/ccopgi/ for
updates to this guideline.
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Appendix 1. Staging System for Soft Tissue Sarcoma
STAGE GROUPING
Stage IA G1,2 T1a N0 M0
G1,2 T1b N0 M0
Stage IB G1,2 T2a N0 M0
Stage IIA G1,2 T2b N0 M0
Stage IIB G3,4 T1a N0 M0
G3,4 T1b N0 M0
Stage IIC G3,4 T2a N0 M0
Stage III G3,4 T2b N0 M0
Stage IV Any G Any T N1 M0
Any G Any T Any N M1
TNM CLINICAL CLASSIFICATION
T-Primary Tumour
TX Primary tumour cannot be assessed
T0 No evidence of primary tumour
T1 Tumour 5 cm or less in greatest dimension
T1a Superficial tumour*
T1b Deep tumour*
T2 Tumour more than 5 cm in greatest dimension
T2a Superficial tumour*
T2b Deep tumour*
Note:*Superficial tumour is located exclusively above the superficial fascia without invasion of the fascia; deep tumour is
located either exclusively beneath the superficial fascia or superficial to the fascia with invasion of or through the fascia.
Retroperitoneal, mediastinal, and pelvic sarcomas are classified as deep tumours.
N-Regional Lymph Nodes
NX Regional lymph nodes cannot be assessed
N0 No regional lymph node metastasis
N1 Regional lymph 
node metastasis
M-Distant Metastasis
MX Distant metastasis cannot be assessed
M0 No distant metastasis
M1 Distant metastasis
G Histopathological Grading
GX Grade of differentiation cannot be assessed
G1 Well differentiated
G2 Moderately differentiated
G3 Poorly differentiated
G4 Undifferentiated
Source: International Union Against Cancer. TNM Classification of Malignant Tumours, fifth edition. New York: Wiley-
Liss; 1997.Adjuvant chemotherapy for resected soft tissue sarcoma 17
Appendix 2. Trial Names and Chemotherapy Regimens Used in Published Studies
GOG11 = Gynecological Oncology Group
Regimen: doxorubicin 60 mg/m2 i.v. every 3 weeks for eight doses.
No concurrent RT.
DFCI12 = Dana Farber Cancer Institute
Regimen: doxorubicin 90 mg/m2 i.v. every 3 weeks for five doses.
Concurrent RT 62.5–67.5 Gy over 6.5–7.0 weeks, with reduced volumes after 45 Gy.
ECOG13 = Eastern Cooperative Oncology Group
Regimen: doxorubicin 70 mg/m2 i.v. every 3 weeks for seven doses.
No concurrent RT.
SSG14 = Scandinavian Sarcoma Group
Regimen: doxorubicin 60 mg/m2 i.v. every 4 weeks for nine cycles.
Concurrent RT in patients with marginal resection, 51 Gy in 17 fractions over 24 days; for retroperitoneal tumours only 
42 Gy.
Rizzoli15,16 = Instituto Ortopedico Rizzoli
Regimen: doxorubicin 25–30 mg/m2 i.v. days 1, 2 and 3, every 3 weeks for six cycles (or a total dose of 450 mg/m2).
Concurrent RT in patients with marginal resection, 45 Gy over 3 weeks.
Intergroup18,19 = Intergroup Sarcoma Study Group
Regimen: doxorubicin 35 mg/m2 (escalated to 45 mg/m2) on days 1 and 2, every 3 weeks up to a total doxorubicin dose 
of 450 mg/m2.
Concurrent RT (dose not given) for patients with ‘conservative resection’.
MDAH20 = M. D. Anderson Hospital
Regimen VACAR: Vincristine 2 mg every week for 9 weeks, then every 3 weeks on day 1; doxorubicin 60 mg/m2 on day 
2 (up to a total dose 420 mg/m2, and cyclophosphamide 200 mg/m2 orally days 3–5; actinomycin D 0.3 mg/m2 i.v. days 
1–5 (maximal single dose 0.5 mg) after doxorubicin total dose achieved. Cycles every 4 weeks while on doxorubicin, 
then every 8 weeks; total duration of chemotherapy 2 years.
Concurrent RT 55 Gy over 6.5 weeks plus 10 Gy to scar.
Mayo21,22 = Mayo Clinic
Regimen VAC/VAD: (1) VAC: vincristine 1.2 mg/m2 days 1 and 5, cyclophosphamide 250 mg/m2 on days 1, 3 and 5, 
and actinomycin D 0.325 mg/m2 days 1–5; and (2) VAD: vincristine 1.2 mg/m2 days 22 and 26, doxorubicin 50 mg/
m2 on day 24, and DTIC 250 mg/m2 on days 22–26.
All drugs given i.v., in 6-week cycles, repeated six times.
No concurrent RT.
In addition, seven patients received MER-BCG on day 1 of each cycle of chemotherapy; then discontinued because 
chronic painful ulcers.
NCI23–26 = National Cancer Institute, Bethesda, USA
Regimen AC/MTX: (1) AC: doxorubicin 50 mg/m2 (escalated up to 70 mg/m2) and cyclophosphamide 500 mg/m2. 
Both i.v. day 1; cycles every 28 days until reaching a total doxorubicin dose of 550 mg/m2.
(2) MTX: Afterwards, methotrexate 50 mg/m2 (escalated up to 250 mg/m2) i.v. infusion over 6 h on day 1, followed 
within 2 h by leucovorin 15 mg i.v. every 6 h for eight doses, or more if methotrexate blood level >4×10-7; cycles every 
4 weeks up to a total maximal methotrexate dose of 1000 mg/kg.
Concurrent RT 60 Gy in 30–35 fractions; field size reduced after 45 Gy.
Six patients also received immunotherapy with Corynebacterium parvum.
EORTC27 = European Organization for Research and Treatment of Cancer
Regimen CYVADIC: cyclophosphamide 500 mg/m2, vincristine 1.5 mg/m2 (maximum dose 2 mg) and doxorubicin 50 
mg/m2 on day 1, and DTIC 400 mg/m2 on days 1–3. All drugs given i.v. every 4 weeks, eight times.
Concurrent RT in some patients, 40 Gy in 4 weeks for pelvic tumours, and 50 Gy for tumours outside the pelvis.
Bergonié28 = Fondation Bergonié
Regimen CYVADIC: Drug doses as in EORTC regimen but cycles every 3 weeks, initially planned for 11 cycles, 
reduced to nine cycles after four patients had major toxicity.
Concurrent RT 50 Gy in 5 weeks plus 10–15 Gy boost to tumour bed. For retroperitoneal and deep abdominal
tumours
RT dose decreased to 40 Gy over 5 weeks and 10 Gy boost; doxorubicin deleted during RT.
Brodowicz29 = Austrian Cooperative Soft Tissue Sarcoma Study Group
Regimen IFADIC: ifosfamide 1500 mg/m2 i.v. plus mesna on days 1–4, DTIC 200 mg/m2 i.v. on days 1–4, and 
doxorubicin 25 mg/m2 i.v. on days 1 and 2. IFADIC administered in a 14-day cycle for a total of six cycles. G-CSF 
(30×106 IU/day) was injected s.c. on days 5–13. Concurrent RT during cycles 3 and 4, when doxorubicin is omitted. 
RT dose 50–60 Gy in twice daily fractions of 1.7 Gy.
Frustaci30 = Italian Randomized Cooperative Trial
Regimen: epirubicin 60 mg/m2 i.v. on days 1 and 2 and ifosfamide 1800 mg/m2 mesna i.v. days 1–5, repeated every 3 
weeks for five cycles; G-CSF rescue. RT given as either post-operative course (64–66 cGY in 33 or 34 fractions, or a 
pre-operative course (44.8 cGy in 28 fractions)18 Figueredo et al.
Petrioli31 = University of Siena
Regimen: epirubicin 75 mg/m2 i.v. every 21 days; or epirubicin 20 mg/m2 i.v. daily for 3 days and ifosfamide 1200 mg/
m2 i.v. daily for 5 days plus mesna; both regimens for four cycles. RT given to some patients: 55–60 cGy for extremity 
sarcomas, and 45–50 cGy for retroperitoneal sarcomas.
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